Application

SIGMAFAST^™ Protease Inhibitor Tablets has been used to collect tracheae in combination with ice-cold radioimmunoprecipitation assay buffer in a study to determine the tracheal basal cell fate. It has been used to homogenize rat lung tissues for western blot analysis.

Optimized and tested for general use.

Components

AEBSF, 2 mMAprotinin, 0.3 µMBestatin, 130 µMEDTA, 1 mME-64, 14 µMLeupeptin, 1 µM

Legal Information

SIGMAFAST is a trademark of Sigma-Aldrich Co. LLC

Other Notes

Tableted formulation containing water-soluble protease inhibitors with broad specificity for the inhibition of serine, cysteine, and metalloproteases. Contains 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), E-64, bestatin, leupeptin, aprotinin, and EDTA (sodium salt).

Physical form

Tablet that is water soluble.

Quantity

One tablet makes 100 mL of cocktail. One mL is recommended for the inhibition of proteases equivalent to 1 mg of USP pancreatin. One tablet is recommended for the inhibition of proteases present in a maximum of 20 g of cell extract.

Specificity

Inhibits serine, cysteine, aspartic, and metalloproteases.